46. Risk Predictors of Lower-limb Amputation in Patients with Type 2 Diabetes Mellitus in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

1 NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
2 School of Medicine, University of Melbourne, Melbourne, Australia
3 Royal Brisbane and Women’s Hospital, Brisbane, Australia
4 Department of Medicine, University of Kuopio, Kuopio, Finland
5 Middlemore Hospital, Auckland, New Zealand

Introduction: Lower limb amputations associated with type 2 diabetes have major implications for morbidity and mortality. The aim of this analysis was to identify important risk predictors for future lower limb amputation on the basis of a large cohort of 9795 patients with type 2 diabetes mellitus in the FIELD study.

Methods: Patients were randomised to receive fenofibrate 200 mg/day or matching placebo over five years, and amputation events (a prespecified tertiary endpoint) were documented at six-monthly intervals. Time to cardiovascular disease events and death according to the predicted risk of amputation was also evaluated. Multivariable proportional-hazards regression analysis using exhaustive-search methods was used to develop predictive models.

Results: The main predictors of the first on-study amputation were a history of previous diabetic skin ulcer or gangrene (HR 3.0), peripheral vascular disease (HR 2.6), hypertension (HR 2.04) and height (HR 1.5 per 10 cm taller) (all P<0.001). Other significant predictors included smoking, albuminuria, HBA1c, retinopathy and PTCAs. Increasing risk of cardiovascular disease events and death was associated with increasing model-predicted amputation risk (P<0.001).

Conclusion: Classical markers of macrovascular and microvascular risk predicted amputations. We also identified height as a major predictor of diabetic amputations, independent of the presence of neuropathy, confirming a previous report from an observational study. These findings could enable more aggressive targeting of modifiable risk factors among patients at high risk of amputations and cardiovascular events who would benefit most from therapeutic intervention.

doi:10.1016/j.hlc.2011.05.049

47. Single-pill Combination of Telmisartan 80 mg/Amlodipine 10 mg Provides Superior Blood Pressure Reductions in Patients with Severe Hypertension: Teamsta Severe HTN Study

1 Orange County Research Center, CA, USA
2 University of Milano-Bicocca, San Gerardo Hospital, Milan, Italy
3 New York University School of Medicine, NY, USA
4 Sahlgrenska University Hospital/Ostra, Sweden
5 Boehringer Ingelheim Pharmaceuticals Inc, CT, USA
6 Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany

Purpose: Investigate the efficacy and safety of the single-pill combination of telmisartan 80 mg/amlodipine 10 mg (T80/A10) vs. its respective monotherapy components in patients with severe hypertension.

Methods: An eight-week, double-blind, parallel-group study, in 808 patients aged ≥18 years with severe hypertension (i.e. SBP ≥180 and DBP ≥95 mm Hg) randomised to T80/A10 (n = 421) or to monotherapy with T80 (n = 217) or A10 (n = 220). The primary endpoint was change from baseline in seated trough cuff SBP.

Results: Baseline characteristics were comparable between the treatment groups. At eight weeks, significantly greater reductions from baseline in seated trough SBP/DBP were observed with T80/A10 vs. T80 or A10 monotherapy, with superior reductions evident at one week. BP control and response rates were consistently higher with T80/A10 vs. T80 or A10 alone. Treatment-related AEs were less frequent with T80/A10 (12.6%) vs. T80 or A10 (16.4%), with a numerically lower incidence of peripheral oedema and rate of treatment discontinuation.

Conclusions: Treatment of severe hypertensive patients with a single-pill combination containing T80/A10 results in significantly greater BP reductions (−47.5/−18.7 mm Hg) and higher BP control/response rates than the respective monotherapies. The safety pro-
file of T80/A10 single-pill combination was comparable to that of its respective components.

doi:10.1016/j.hlc.2011.05.050

48 Sleep Disordered Breathing in Children is Associated with Increased Platelet Aggregation, Systemic Inflammation and Endothelial Dysfunction
S. Willoughby1,2, C. van den Heuvel1, A. Chin1, G. Hodge3, J. Martin2, A. Nelson1,3, M. Worthley1,2, D. Kennedy1
1 University of Adelaide, Australia
2 Women’s and Children’s Hospital, Australia
3 Royal Adelaide Hospital, Australia

Introduction: Sleep disordered breathing (SDB) in adults is an independent risk factor for coronary artery disease and stroke. Altered platelet reactivity, endothelial dysfunction and inflammation in adults with SDB are known to contribute to the pathogenesis of its cardiovascular complications. Sleep disordered breathing also occurs in children; however little is known about these parameters in non-obese children with SDB. Therefore, this study investigated platelet aggregation, inflammation and endothelial function in children with SDB and healthy matched controls.

Methods: Clinical evaluation of SDB was performed on 19 children aged 5-16 years through polysomnography (n=12 were clinically diagnosed with SDB, n=7 were controls). Venous blood samples were collected and analysed for measurements of platelet aggregation and inflammation. Platelet aggregation was assessed by the Multiplate analyzer. Inflammation was assessed by intracellular cytokine analysis of T cell by flow cytometry. Plasma asymmetric dimethylarginine (ADMA), a marker of endothelial function, was also quantified.

Results: Platelet aggregation was significantly increased in SDB subjects compared to controls (56.7 ± 16.8 aggregation units (AU) vs. 38.3 ± 4.0 AU, p<0.05). There was a significant increase in inflammation measured by T-cell interferon (IFN)-gamma (SDB 52 ± 4% vs controls 25 ± 3% positive cells, P<0.005) and tumour necrosis factor (TNF)-alpha (SDB 39 ± 4% vs controls 20 ± 2% positive cells, P<0.005) in SDB children compared with controls. Children with SDB also exhibited higher ADMA levels (0.43 ± 0.5 vs controls 0.35 ± 0.06 µmol/l, P<0.05).

Conclusion: Sleep disordered breathing in children is associated with enhanced platelet aggregation, endothelial dysfunction and inflammatory responses. These parameters may contribute to an increased cardiovascular risk for children with SDB.

doi:10.1016/j.hlc.2011.05.051